The numbers alone sound absurd. A single biologic drug can cost $150,000 a year. The paperwork to approve it? That can take weeks—and often ends in denial anyway.
For rheumatology clinics, the math is even worse. Staff juggle access to 70 different insurance portals. Each payer wants different forms, different lab results, different proof that the patient has tried and failed other therapies first. One in five requests gets rejected outright, according to clinic data, forcing everyone back to square one.
Meng Fei Shen spent years inside that system. As an infusion coordinator at San Mateo Rheumatology, she watched patients wait while staff chased down authorizations for six-figure drugs. She saw physicians burn 13 hours a week on prior auth paperwork instead of treating patients. And when she and co-founder Christina Huang—herself a biologics patient—launched Ruma Care out of Y Combinator this winter, they had a specific target in mind: cut that denial rate in half.
Early numbers suggest they might be onto something. Clinics in California and Nevada report denial rates dropping by 50% and processing times accelerating by a factor of 20, according to the company's launch materials. It's still early. But in a market where 37% of denied prescriptions simply get abandoned—patients giving up rather than fighting the system—even incremental gains matter.
Medical Benefit, Maximum Friction
Ruma isn't trying to fix all of healthcare's prior authorization mess. It's going after a specific slice: specialty biologics billed under medical benefit, not pharmacy benefit. These are the drugs infusion clinics buy directly, then bill to insurers using J-codes—a world of higher costs and far less standardization than the pharmacy ePA systems that companies like CoverMyMeds have dominated for years.
The workflow Ruma automates looks deceptively simple on paper. Pull patient data from electronic health records. Match the right prior authorization form to the medication, diagnosis, and insurer. Assemble the submission packet, complete with lab results and therapy histories. Flag any gaps before it goes to the payer.
Simple, perhaps. But also the kind of administrative burden that forces specialty practices to dedicate full-time employees to nothing but paperwork.
"We've been able to get patients started on therapy so much faster," said Janeen Thompson, a staffer at San Mateo Rheumatology, in a testimonial the company shared publicly.
The platform also handles copay program enrollment—another layer of bureaucracy in a system where patients often owe thousands of dollars out of pocket—and tracks reimbursement to make sure clinics actually get paid for the expensive drugs they've already purchased.
A Market Built on Denials
The stakes here are larger than they might first appear. Biologics now account for roughly 46% of U.S. drug spending, according to IQVIA market data. Some medications carry list prices north of $180,000 a year for specific indications. Stelara, used for gastrointestinal maintenance therapy, is one example frequently cited in pricing debates.
And yet access remains tightly controlled. Payers require prior authorization on most high-cost biologics, ostensibly to ensure medical necessity and appropriate use. In practice, the process creates friction—sometimes so much friction that patients abandon treatment altogether rather than navigate months of appeals.
Ruma launched publicly in early February, focusing initially on rheumatology clinics. The platform could theoretically extend to gastroenterology, dermatology, and neurology practices that administer high-cost infusions, though the company hasn't disclosed expansion plans in detail.
Co-founder Christina Huang brings a patient's perspective to the work. In a LinkedIn post announcing Ruma's acceptance into Y Combinator's Winter 2026 batch, she described the frustration of navigating prior auths for her own treatment—a lived experience that now informs the product's design. Before Ruma, Huang worked on integrations at Medallion, including projects with UnitedHealth, and held roles at Apple and Bloomberg. Shen's resume spans product work at Uber and Walmart Data Ventures, along with her frontline experience coordinating infusions.
Crowded Space, Narrow Wedge
Ruma is hardly the first company to promise prior authorization relief. CoverMyMeds, now owned by McKesson, dominates the pharmacy-benefit ePA market, though some large payers have shifted volume to Surescripts in recent years. SamaCare has carved out traction in specialty drug PA and recently integrated with WeInfuse, a major infusion center software platform. Myndshft markets unified medical and pharmacy PA automation. RxLightning offers enrollment and PA tools for specialty medications.
What Ruma is betting on—perhaps the only real differentiation available—is that infusion clinics need something purpose-built for medical-benefit biologics. The company emphasizes pre-validation: catching missing documentation before the request ever reaches the payer, rather than just routing forms through the system faster.
Whether that's enough to build a sustainable business remains an open question. The company's early metrics come from a small base of live customers, and scaling beyond rheumatology will test whether the platform's approach translates to other specialties.
Timing may help. New CMS interoperability rules require impacted payers to implement prior authorization APIs by January 2027, with operational requirements already taking effect as of this January. Some large pharmacy benefit managers—Optum Rx among them—have started cutting PA requirements for dozens of drugs in response to pressure from providers and patient advocates.
But biologics remain heavily gated, and for now, most infusion clinics are still logging into 70 different portals and filling out forms by hand.
What Happens Next
The pitch Ruma is making to clinics is straightforward, almost blunt: automate the busywork, cut the denials, get patients on therapy faster. It's a value proposition rooted in hours saved and revenue recovered—practical concerns for practices operating on thin margins while fronting the cost of six-figure drugs.
Whether Shen and Huang can scale that pitch beyond their initial customer base, and whether the 50% denial reduction holds up as the platform expands, will determine if Ruma becomes a meaningful player in the prior auth space or just another vendor in an already crowded market.
For patients waiting weeks to start treatment while insurers demand one more form, one more lab result, one more proof of medical necessity, the answer can't come soon enough. The question is whether software alone can fix a system that's become this tangled—or whether the real problem runs deeper than any startup can reach.
